RxDoctor Payments DataLook up a doctor →

Savitha Balaraman, MD

Medical Oncology · Madison Heights, MINPI 1083696694

Payments from drug & device makers

$268,527in general payments, 2019–2025

Across 226 payments — averaging $1188.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$81K
  • Epizyme, Inc.$32K
  • AstraZeneca$29K
  • Novocure GmbH$28K
  • Morphosys AG$20K
  • Bayer$16K
  • plus $63K from 37 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer35$80,848
Epizyme, Inc.10$31,677
AstraZeneca6$29,197
Novocure GmbH16$28,165
Morphosys AG2$20,000
Bayer4$16,001
Tolmar, Inc.6$13,950
Amgen13$13,760
Genentech, Inc.6$13,700
Jazz Pharmaceuticals Inc.5$8,850
Veru Inc.1$5,400
Merck9$2,899
Immunomedics, Inc.1$1,575
Johnson & Johnson(2 entities)4$246
Seagen Inc.10$222
Novartis11$218
AVEO Pharmaceuticals, Inc.13$196
Astellas Pharma US Inc10$162
Gilead(2 entities)11$157
Genentech USA, Inc.9$146
Foundation Medicine, Inc.2$142
Avyxa Pharma, LLC1$132
Exelixis Inc.1$122
Mirati Therapeutics, Inc.5$85
Sanofi-aventis U.S. LLC1$65
Nestle Healthcare Nutrition Inc.3$65
Regeneron Healthcare Solutions, Inc.3$54
AMAG Pharmaceuticals, Inc.4$52
Sanofi2$51
Pharmaessentia USA Corporation2$47
EMD Serono, Inc.3$40
Blueprint Medicines Corporation2$37
Bristol Myers Squibb2$34
Ipsen Biopharmaceuticals, Inc2$34
Morphosys, US Inc.2$32
Array Biopharma Inc2$31
Pharmacyclics LLC, An Abbvie Company1$24
Karyopharm Therapeutics Inc.1$22
E.r. Squibb & Sons, L.L.C.1$22
Taiho Oncology, Inc.1$22
Daiichi Sankyo Inc.1$17
Rigel Pharmaceuticals, Inc.1$17
Myovant Sciences Inc.1$14

How this compares

$268,527 in reported general payments places this provider in the 65th percentile of 170 medical oncology providers in Michigan.

See all medical oncology providers in Michigan →

Medicare billing

Part B allowed, 2024
$3,997,079
Medicare patients
691
Services billed
220,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Madison Heights

See the full list for Michigan →

Where these figures come from

Is this you, or does something look wrong? →